These findings demonstrate that blocking the IL-4/IL-13 pathway with dupilumab can be an effective treatment with long-term safety in patients with severe AERD with CRS complicated by IgG4RD. This evidence concerns the gene IL13 and immunoglobulin G4-related sclerosing disease.